락토바실루스 카세이 관련 항생제 관련 설사(AAD)
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.입원 노인 환자의 AAD 예방에 대한 일부 근거가 있습니다(PLACIDE 시험은 주요 결과에서 음성이었으나 경향성을 보임).
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dcasei\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
입원 노인 환자의 AAD 예방에 대한 일부 근거가 있습니다(PLACIDE 시험은 주요 결과에서 음성이었으나 경향성을 보임).
Key Study Findings
In Vitro
Complex probiotics alleviate ampicillin-induced antibiotic-associated diarrhea in mice.
Dose: 4-strain probiotic mixture
vs: Ampicillin-induced AAD model
Outcome: Gut microbiota recovery and immune modulation
효과: None
None
대상 집단: Ampicillin-induced AAD mouse model
Meta-Analysis
n=692
Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and …
Dose: None
vs: Control group
Outcome: the incidence rates of AAD and CDAD, and …
효과: OR 0.39,
None
대상 집단: Diarrhea patients
Randomized Controlled Trial
n=314
4.3 weeks
Double-blind
Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial.
Dose: None
vs: Placebo
Outcome: Bowel function
효과: None
p=0.30
대상 집단: None
Systematic Review
n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None
vs: None
Outcome: Diarrhea outcomes
효과: None
None
대상 집단: None
Controlled Clinical Trial
n=32
4.3 weeks
Open-label
Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic …
Dose: 10 billion L. casei, 2 bottles/day
vs: Contemporary matched controls
Outcome: Safety, feasibility, AAD incidence
효과: None
None
대상 집단: ICU patients on antibiotics
Meta-Analysis
n=9569
Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis.
Dose: None
vs: Placebo/no probiotic
Outcome: Prevention of antibiotic-associated diarrhea
효과: LGG OR 0.28 (0.17-0.47) for AAD prevention
None
대상 집단: Patients on antibiotics
Key Statistics
3
연구
500
참여자
↑
Positive
C
등급
Referenced Papers
Frontiers in microbiology
2023
21 인용
Journal of digestive …
2020
43 인용
Journal of clinical …
2019
17 인용
Frontiers in medicine
2018
450 인용
United European gastroenterology …
2018
66 인용
Nutrients
2018
50 인용
F1000Research
2016
63 인용
Antibiotics (Basel, Switzerland)
2015
104 인용
Clinical infectious diseases …
2015
59 인용
World journal of …
2014
73 인용
Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea.
Other
Journal of medical …
2012
28 인용
Revista da Sociedade …
2012
13 인용
Journal of clinical …
2011
432 인용
The American journal …
2010
313 인용
Canadian journal of …
2007
182 인용
Acta paediatrica Taiwanica …
2004
6 인용
International journal of …
2000
181 인용
The Journal of …
1999
559 인용
Anaerobe
1997
40 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- aadprevention:
- 6.5 billion CFU/day (Shirota strain)
- immunesupport:
- 10 billion CFU/day
상한량: Well-tolerated up to 20 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| 4-strain probiotic mixture | -- | Positive | -- |
| None | -- | Positive | 692 |
| None | 4.3 weeks | Neutral | 314 |
| None | -- | Mixed | 228 |
| 10 billion L. casei, 2 bottles/day | 4.3 weeks | Positive | 32 |
| None | -- | Positive | 9569 |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
권장 복용 시간: With or without food; consistent daily timing recommended
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Rare dairy-related reactions in lactose-sensitive individuals
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 20 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 락토바실루스 카세이 help with 항생제 관련 설사(AAD)?
Based on 3 studies with 500 participants, there is limited but promising evidence that 락토바실루스 카세이 may support 항생제 관련 설사(AAD) management. Our evidence grade is C (Some Evidence).
How much 락토바실루스 카세이 should I take for 항생제 관련 설사(AAD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 락토바실루스 카세이?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare dairy-related reactions in lactose-sensitive individuals, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 락토바실루스 카세이 and 항생제 관련 설사(AAD)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 항생제 관련 설사(AAD)
References
- [1] Wenwen Li et al.. Front Microbiol. 2023. Complex probiotics alleviate ampicillin-induced antibiotic-associated diarrhea in mice. doi:10.3389/fmicb.2023.1156058 PubMed
- [2] Yan Ma et al.. J Dig Dis. 2020. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. doi:10.1111/1751-2980.12839 PubMed
- [3] María Velasco et al.. J Clin Gastroenterol. 2019. Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial. doi:10.1097/MCG.0000000000001131 PubMed
- [4] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
- [5] Jiayi Cai et al.. United European Gastroenterol J. 2018. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. doi:10.1177/2050640617736987 PubMed
- [6] Cathy Alberda et al.. Nutrients. 2018. Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile. doi:10.3390/nu10050539 PubMed
- [7] Sunit C Singhi et al.. F1000Res. 2016. Probiotics in critically ill children. doi:10.12688/f1000research.7630.1 PubMed
- [8] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
- [9] Julie Auclair et al.. Clin Infect Dis. 2015. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of … doi:10.1093/cid/civ179 PubMed
- [10] Christoph G Dietrich et al.. World J Gastroenterol. 2014. Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea. doi:10.3748/wjg.v20.i42.15837 PubMed
- [11] Alvine Adrienne Kamdeu Fansi et al.. J Med Econ. 2012. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. doi:10.3111/13696998.2011.629015 PubMed
- [12] Daniela Nogueira Prado de Souza et al.. Rev Soc Bras Med Trop. 2012. The effect of Lactobacillus casei and Bifidobacterium breve on antibiotic-associated diarrhea treatment: randomized double-blind clinical trial. doi:10.1590/s0037-86822012000100021 PubMed
- [13] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
- [14] Xing Wang Gao et al.. Am J Gastroenterol. 2010. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium … doi:10.1038/ajg.2010.11 PubMed
- [15] M Beausoleil et al.. Can J Gastroenterol. 2007. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, … doi:10.1155/2007/720205 PubMed
- [16] Yu-Kung Chou et al.. Acta Paediatr Taiwan. 2004. In vitro antibiotic susceptibility of lactobacilli isolated from commercial products containing active lactobacilli. PubMed
- [17] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
- [18] J A Vanderhoof et al.. J Pediatr. 1999. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. doi:10.1016/s0022-3476(99)70053-3 PubMed
- [19] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.